A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

Genocury Biotech, a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress platform, announced groundbreaking clinical data from its noval in vivo ...

This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients.

Unlike conventional CAR-T, which carries a ~50% risk of cytokine ... Cytokine release syndrome (CRS) Immune effector cell-associated neurotoxicity syndrome (ICANS) Lymphodepletion-related ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer ... KTE-X19 (autologous anti-CD19-transduced CD3+ cells) for relapsed or ...

"but it could also be the case that LICATS indeed is less common following CD19-targeting CAR T-cell therapy of B-cell malignancies, as the organ distribution of malignant B cells follows other ...

Caribou Biosciences, Inc.’s CRBU share price has surged by 5.65%, which has investors questioning if this is right time to ...

Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage ... Cytokine release syndrome (CRS) Immune effector cell-associated neurotoxicity syndrome (ICANS) Lymphodepletion ...

Unlike conventional CAR-T, which carries a ~50% risk of cytokine release syndrome (CRS) and neurotoxicity, this novel therapeutic approach demonstrated complete absence of: Cytokine release syndrome ...